Digitisation | November 14, 2023
Bayer and Recursion focus research collaboration on Oncology
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
This collaboration underscores WOTR's unwavering commitment to strengthening rural communities against the unpredictable variations of climate change
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Lack of technology transfer stands out as a formidable barrier
The newly developed adhesive is available in two different grades. Loctite WT 3001 and Loctite WT 3003 h
The agreement demonstrates a shared commitment to advance precision medicine and improve patient outcomes in the region
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
RHTC will address a long-standing healthcare access issue for all the local population
Short-term treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD)
Subscribe To Our Newsletter & Stay Updated
